ultrasonic-scientific

derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells

Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells

We carried out a Part I scientific trial of donor derived CD19-specific chimeric antigen receptor T-cells (CAR T-cells) for B-cell malignancy that relapsed or endured after matched associated allogeneic hemopoietic stem cell transplant. To beat the associated fee and transgene capability limitations of conventional viral vectors, CAR T-cells have been produced utilizing the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, one affected person developed a progressively enlarging retroperitoneal tumor on account of a CAR expressing CD4+ T-cell lymphoma. Screening of different sufferers led to the detection of a second CAR T-cell tumor in thoracic para-aortic lymph nodes in an asymptomatic affected person.

Evaluation of the primary lymphoma confirmed a excessive transgene copy quantity, however no insertion into typical oncogenes. There have been additionally structural modifications comparable to altered genomic copy quantity and level mutations unrelated to the insertion websites. Transcriptome evaluation confirmed transgene promoter pushed upregulation of transcription of surrounding areas regardless of insulator sequences surrounding the transgene. Nevertheless, marked international modifications in transcription predominantly correlated with gene copy quantity slightly than insertion websites.

In each sufferers, the CAR T-cell derived lymphoma progressed and one affected person died. We describe the primary two instances of malignant lymphoma derived from CAR gene modified T-cells. Though CAR T-cells have an enviable report of security to this point, our outcomes emphasize the necessity for warning and common comply with up of CAR T recipients, particularly when novel strategies of gene switch are used to create genetically modified immune therapies. The trial was registered at www.anzctr.org.au as ACTRN12617001579381.

Reminiscence stem T cells modified with a redesigned CD30-chimeric antigen receptor present an enhanced antitumor impact in Hodgkin lymphoma

Goals: Adoptive cell remedy (ACT) with mature T cells modified with a chimeric antigen receptor has demonstrated improved consequence for B-cell malignancies. Nevertheless, its utility for others comparable to Hodgkin lymphoma stays a scientific problem. CD30 antigen, expressed in Hodgkin lymphoma cells, is absent in most wholesome tissues, representing a perfect goal of ACT for this illness. Regardless of that, efficacy of CD30-chimeric antigen receptor (CAR) T cells for Hodgkin lymphoma stays modest. Right here, now we have developed and examined a novel CD30-CAR T to enhance efficacy of CD30-CAR remedy, utilizing a concentrating on epitope inside the non-cleavable a part of CD30 receptor, and reminiscence stem T cells (TSCM) to enhance engraftment, persistence and antitumor exercise.

Strategies: TSCM-like cultures have been generated and expanded ex vivo and transduced at day 1 or 2 with a lentiviral vector encoding the CD30-CAR. Therapeutic in vivo experiments have been carried out utilizing NSG mice injected with L540 (sc) or L428 (iv) and handled with CD30-CAR T cells when the tumor was established.

Outcomes: CD30-CAR TSCM-like cells generated and expanded ex vivo, regardless of CD30 expression and fratricide killing of CD30+ CAR T cells, weren’t impaired by soluble CD30 and utterly eradicated Hodgkin lymphoma in vivo, displaying excessive persistence and long-lasting immunity. As well as, extremely enriched CD30-CAR TSCM-like merchandise confer a survival benefit in vivo, in distinction to extra differentiated CAR T cells, with greater tumor infiltration and enhanced antitumor impact.

Conclusion: This research helps using a refined CD30-CAR T cells with extremely enriched TSCM-like merchandise to enhance scientific efficacy of CAR T for Hodgkin lymphoma.

Chimeric antigen receptor T cells concentrating on CD7 in a toddler with high-risk T-cell acute lymphoblastic leukemia

Efficient systemic therapies for relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) are restricted. Current scientific utility of chimeric antigen receptor (CAR) immunotherapy has demonstrated profitable management of B-cell malignancies by CAR-T cells; nonetheless, designing CARs for T-ALL stays a problem. CD7 overexpression in T-cell malignancies could also be a horny goal for immunotherapy in T-ALL. This research aimed to explain the protected and efficient use of autologous CD7-CAR T cells (4SCAR7) for the therapy of T-ALL with induction failure in an 11-year-old affected person. Based mostly on The Chinese language Youngsters’s Most cancers Group-ALL (CCCG-ALL) research protocol, minimal residual illness (MRD) by move cytometry (FC) evaluation was detected on days 19 and 46 of remission induction.

On the finish of remission-induction chemotherapy, the affected person achieved morphologic full remission, although with MRD 16.13% and RT-PCR of KMT2A-MLLT1 fusion constructive, which indicated induction failure. The cerebrospinal fluid (CSF) was damaging for blasts at identified. CAR-T remedy and allogeneic transplant have been really helpful as the subsequent therapy choices. CD3+ lymphocytes have been collected from the affected person 18 days after the high-dose MTX chemotherapy by means of leukapheresis. The 4SCAR7 CD7-targeting CAR-T cells have been generated thereafter.

The affected person acquired lymphodepleting chemotherapy previous to 4SCAR7 infusion. Oral administration of itraconazole and sulfamethoxazole was carried out from day zero after CAR-T cell infusion. The affected person didn’t have hypotension, hypoxia, or severe biochemical change or abnormality, however had fever on day 9. Though grade 1 cytokine-release syndrome (CRS) was identified, it was efficiently handled with ibuprofen. Anti-CD7 CAR transgene copy numbers in peripheral blood have been decided by qPCR, which confirmed efficient enlargement initially, then dropped shortly, and endured at a low stage. Though skilled cytopenia from days 14 to 21, the affected person achieved remission on day 17. After full remission, the affected person acquired hematopoietic stem cell transplantation (HSCT) and has recovered effectively to thisdate. Total, this report advised that 4SCAR7 might be a protected and efficient technique for the therapy of pediatric sufferers with high-risk T-cell malignancies.

ultrasonic-scientific
ultrasonic-scientific

OCOA13214-20UG - EBAG9 Protein Lysate

OCOA13214-20UG 20ug
EUR 169

OCOA04155-20UG - EBAG9 Protein Lysate

OCOA04155-20UG 20ug
EUR 169

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9)

1-CSB-EP007355HU
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells(EBAG9),partial expressed in E.coli

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

20-abx112338
  • Ask for price
  • Ask for price
  • 150 ul
  • 50 ul

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

20-abx123391
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx031290-400ul 400 ul
EUR 627.6

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx031290-80l 80 µl
EUR 343.2

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx037482-100ug 100 ug
EUR 469.2

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx037831-100ug 100 ug
EUR 469.2

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

20-abx001581
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx430429-200ul 200 ul
EUR 460.8

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx112338-100l 100 µl
EUR 612.5

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx037482-96tests 96 tests
EUR 337.5

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx037831-96tests 96 tests
EUR 337.5

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx031290-400l 400 µl
EUR 518.75

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx237203-100g 100 µg
EUR 350

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx237204-100g 100 µg
EUR 350

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx430429-200l 200 µl
EUR 387.5

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx001581-100l 100 µl
EUR 400

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx001581-20l 20 µl
EUR 175

Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) Antibody

abx001581-50l 50 µl
EUR 275

Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512994-96tests 96 tests
EUR 1093.2

Rat Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512997-96tests 96 tests
EUR 801.6

Dog EBAG9 / Receptor-binding cancer antigen expressed on SiSo cells ELISA Kit

E0449d 96T
EUR 900

Rat Ebag9 / Receptor-binding cancer antigen expressed on SiSo cells ELISA Kit

E0449r 96T
EUR 796

Rat Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

RK06836 96T
EUR 280

Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512994-1096tests 10 × 96 tests Ask for price

Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512994-596tests 5 × 96 tests Ask for price

Pig Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9310798-10x96StripWells 10x96-Strip-Wells
EUR 6725

Pig Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9310798-48StripWells 48-Strip-Wells
EUR 550

Pig Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9310798-5x96StripWells 5x96-Strip-Wells
EUR 3420

Pig Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9310798-96StripWells 96-Strip-Wells
EUR 765

Rat Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9329289-10x96StripWells 10x96-Strip-Wells
EUR 6725

Rat Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9329289-48StripWells 48-Strip-Wells
EUR 550

Rat Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9329289-5x96StripWells 5x96-Strip-Wells
EUR 3420

Rat Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9329289-96StripWells 96-Strip-Wells
EUR 765

Dog Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9323204-10x96StripWells 10x96-Strip-Wells
EUR 6725

Dog Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9323204-48StripWells 48-Strip-Wells
EUR 550

Dog Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9323204-5x96StripWells 5x96-Strip-Wells
EUR 3420

Dog Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9323204-96StripWells 96-Strip-Wells
EUR 765

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512995-96tests 96 tests
EUR 801.6

Mouse Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512996-96tests 96 tests
EUR 801.6

Human EBAG9/ Receptor-binding cancer antigen expressed on SiSo cells ELISA Kit

E0748Hu 1 Kit
EUR 515
Description: RCAS1,Cancer-associated surface antigen RCAS1,Estrogen receptor-binding fragment-associated gene 9 protein

Human EBAG9 / Receptor-binding cancer antigen expressed on SiSo cells ELISA Kit

E0449h 96T
EUR 736

Mouse Ebag9 / Receptor-binding cancer antigen expressed on SiSo cells ELISA Kit

E0449m 96T
EUR 776

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

RK06834 96T
EUR 280

Mouse Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

RK06835 96T
EUR 280

Human Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) ELISA Kit

abx259811-1mg 1 mg Ask for price

Human Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) ELISA Kit

abx259811-20g 20 µg Ask for price

Human Receptor-Binding Cancer Antigen Expressed On SiSo Cells (EBAG9) ELISA Kit

abx259811-5g 5 µg
EUR 687.5

Mouse Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512996-1096tests 10 × 96 tests Ask for price

Mouse Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

abx512996-596tests 5 × 96 tests Ask for price

Mouse Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9322031-10x96StripWells 10x96-Strip-Wells
EUR 6725

Mouse Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9322031-48StripWells 48-Strip-Wells
EUR 550

Mouse Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9322031-5x96StripWells 5x96-Strip-Wells
EUR 3420

Mouse Receptor-binding cancer antigen expressed on SiSo cells, EBAG9 ELISA Kit

MBS9322031-96StripWells 96-Strip-Wells
EUR 765

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

MBS280229-10x96StripWells 10x96-Strip-Wells
EUR 6840

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

MBS280229-48StripWells 48-Strip-Wells
EUR 480

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

MBS280229-5x96StripWells 5x96-Strip-Wells
EUR 3610

Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9) ELISA Kit

MBS280229-96StripWells 96-Strip-Wells
EUR 805

Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

MBS1349708-005mgBaculovirus 0.05mg(Baculovirus)
EUR 1115

Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

MBS1349708-005mgMammalianCell 0.05mg(Mammalian-Cell)
EUR 1335

Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

MBS1349708-05mgEColi 0.5mg(E-Coli)
EUR 1115

Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

MBS1349708-05mgYeast 0.5mg(Yeast)
EUR 1335

Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

MBS1349708-1mgEColi 1mg(E-Coli)
EUR 1635

Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1430359-005mgBaculovirus 0.05mg(Baculovirus)
EUR 1115

Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1430359-005mgMammalianCell 0.05mg(Mammalian-Cell)
EUR 1335

Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1430359-05mgEColi 0.5mg(E-Coli)
EUR 1115

Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1430359-05mgYeast 0.5mg(Yeast)
EUR 1335

Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1430359-1mgEColi 1mg(E-Coli)
EUR 1635

Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells(EBAG9),partial

AP70252 1mg
EUR 1978

Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial

CSB-EP007355HU 1056 mg Ask for price

Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1320693-005mgBaculovirus 0.05mg(Baculovirus)
EUR 1115

Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1320693-005mgMammalianCell 0.05mg(Mammalian-Cell)
EUR 1335

Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1320693-05mgEColi 0.5mg(E-Coli)
EUR 1115

Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1320693-05mgYeast 0.5mg(Yeast)
EUR 1335

Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial

MBS1320693-1mgEColi 1mg(E-Coli)
EUR 1635

Protein expression

CRO-4-Ind each Ask for price

EP Reagent Biuret Reagent - 100ML

1011601 1L
EUR 59.4

RFP expression Adenovirus, in vivo ready

AVP001-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made RFP expression adenovirus, provided in PBS solution.

CFP expression Adenovirus, in vivo ready

AVP002-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made CFP expression adenovirus, provided in PBS solution.

GFP expression Adenovirus, in vivo ready

AVP011-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made GFP expression adenovirus, provided in PBS solution.

YFP expression Adenovirus, in vivo ready

AVP012-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made YFP expression adenovirus, provided in PBS solution.

BFP expression Adenovirus, in vivo ready

AVP017-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made BFP expression adenovirus, provided in PBS solution.

PEROXIDE BLOCKING REAGENT Reagent

GWB-Q00308 50 ml Ask for price

YLEX Expression Kit

FYY201-1KT 1 kit Ask for price

EP Reagent Iodoplatinate Reagent - 200ML

1046300 200ML
EUR 502.2

EP Reagent Molybdovanadic Reagent - 100ML

1056700 100ML
EUR 59.4

h OCT4 expression Adenovirus, in vivo ready

AVP013-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made adenovirus express human stem cell factor, OCT4, provided in PBS solution for in vivo application.

h SOX2 expression Adenovirus, in vivo ready

AVP014-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made adenovirus express human stem cell factor, SOX2, provided in PBS solution for in vivo application.

293 Expression MAX-1

EXP-711-11 1ml
EUR 214
Description: 293 Expression MAX-1 is expressed from - -.

EP Reagent Methoxyphenylacetic Reagent - 100ML

1053601 100ML
EUR 490.05

h LIN28 expression Adenovirus, in vivo ready

AVP015-PBS 1x1011 IFU/ml x 50ul
EUR 852
Description: pre-made adenovirus express human stem cell factor, LIN28, provided in PBS solution for in vivo application.

CNGA2 Expression vector

60642 20 µg
EUR 900
Description: The CNGA2 expression vector is designed to express human cyclic nucleotide-gated cation channel 2 (CNGA2) in mammalian cells.

CNGA2 Expression vector

GWB-PSFA61 20ug Ask for price

EP Reagent Phosphomolybdotungstic Reagent - 100ML

1065000 100ML
EUR 226.8

LEXSYcon2.1 Expression Kit

EGE-1310ble 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

LEXSYcon2.1 Expression Kit

EGE-1310bsd 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

LEXSYcon2.1 Expression Kit

EGE-1310hyg 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

LEXSYcon2.1 Expression Kit

EGE-1310neo 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

LEXSYcon2.1 Expression Kit

EGE-1310pac 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

LEXSYcon2.1 Expression Kit

EGE-1310sat 1Kit
EUR 1296.1
Description: for constitutive cytosolic or secretory protein expression

pYLEX1 - Expression Vector

FYY203-5MG 5mg Ask for price

Blunt E1 Expression Kit

abx098098-10rxns 10 rxns
EUR 560.4

Blunt E2 Expression Kit

abx098873-10rxns 10 rxns
EUR 560.4

Blunt E1 Expression Kit

abx098098-100l 100 µl
EUR 712.5

Blunt E1 Expression Kit

abx098098-1ml 1 ml Ask for price

Blunt E1 Expression Kit

abx098098-200l 200 µl Ask for price

Blunt E2 Expression Kit

abx098873-100l 100 µl
EUR 712.5

Blunt E2 Expression Kit

abx098873-1ml 1 ml Ask for price

Affected person-Reported Outcomes for Most cancers Sufferers with Hematological Malignancies Present process Chimeric Antigen Receptor T Cell Remedy: A Systematic Assessment

Databases have been searched to establish research revealed over the previous 10 years that addressed the utility of patient-reported outcomes (PROs) in sufferers receiving chimeric antigen receptor (CAR) T cell remedy in sufferers with hematological malignancies. Amongst 280 data, three articles masking 206 sufferers have been eligible. The info have been prospectively collected at a number of time factors. The compliance charges have been 70% to 94%. There was an inverse relationship between fatigue and social perform amongst adults. The standard of life (QoL) enchancment and skill to finish PROs have been linked to illness standing. About 40% of adults reported no less than some cognitive difficulties, with a detrimental influence on psychological and bodily well being standing. In adults, probably the most generally reported cognitive impairment was reminiscence difficulties.

Melancholy was related to cognitive difficulties. Youthful adults have been at greater threat of long-term poor psychological well being, anxiousness, and despair. For pediatric and adolescent sufferers, emotional dysfunction improves over time. QoL standing improved over time; but, extreme cytokine launch syndrome and neurotoxicity precipitated delayed enchancment. Info concerning whether or not the PROs have been built-in into medical data and scientific tips is missing. Using PROs in sufferers on CAR T cell remedy appears possible and informative. Research using bigger pattern sizes and utilizing validated PRO instruments at completely different time factors stay unmet wants.

Leave a Reply

Your email address will not be published. Required fields are marked *